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In the U.S.A., cocaine is the second most abused illicit drug. Variants within the CHRNB3-A6 gene cluster
have been associated with cigarette consumption in several GWAS. These receptors represent intriguing
candidates for the study of cocaine dependence because nicotinic receptors are thought to be involved in
generalized addiction pathways. Using genotypic data from aGWASof the Study of Addiction: Genetics and
Environment (SAGE) dataset, we tested for association of CHRNB3-A6 SNPs with DSM-5 cocaine use
disorder. Multiple SNPs in the region were significantly associated with increased risk of cocaine use
disorder. Inclusion of themost significant SNP as a covariate in a linear regressionmodel provided evidence
for an additional independent signal within this locus for cocaine use disorder. These results suggest that the
CHRNB3-A6 locus contains multiple variants affecting risk for vulnerability to cocaine and nicotine
dependence as well as bipolar disorder, suggesting that they have pleiotropic effects.
D
rug addiction is a pervasive problem across cultures and is both an economic and psychological burden for
the individuals and families involved. Illicit drugs have particularly devastating consequences: Cocaine
users have six times the mortality rate of their age-matched peers1, and one study found that crack cocaine
was the third most harmful drug overall2. Consequently, a greater understanding of the molecular mechanisms
underlying the risk of developing cocaine dependence is urgently needed to aid in targeting prevention and
treatment strategies.
Susceptibility to drug use, abuse, and dependence has been shown by several studies to have amoderate to high
genetic component3,4. The one year point prevalence, or the proportion of people possessing a phenotype within a
one year timeframe, for substance use disorders in the USA, excluding nicotine has been estimated to be 9.35%3.
The heritability of cocaine dependence (CD) has been estimated from twin studies to be 63–79%5. There have
been two genome-wide linkage studies. The first found suggestive linkage between CD phenotypes of cocaine
induced paranoia, heavy use, and moderate use on chromosomes 9, 12, and 18 respectively (n5 986 individuals
from 390 pedigrees)6. The second study reported genome-wide significant linkage to regions on chromosomes 5
and 7with the phenotype of CD and its co-occurrence withmajor depressive disorder (n5 1896 individuals from
739 families)7. Candidate gene association studies have reported association between a SNP in pro-opiomelano-
cortin POMC (rs6713532) and CD in European-American families8, consistent with the role of the opioidergic
system in addiction and reinforcement. Furthermore, several SNPs in the mannosidase, endo-alpha (MANEA)
gene have also been associated with cocaine-induced paranoia9. Recently, Gelernter and colleagues completed a
GWAS of cocaine dependence in over 4000 European and African-American subjects. They identified rs2329540
in the FAM53B (family with sequence similarity 53, member B) gene to be significantly associated with CD
symptom count in both ethnic groups. Additional variants were also identified at genome-wide significant (GWS)
levels for a diagnosis of CD as well as for cocaine-induced paranoia10.
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In addition to the observed co-occurrence of cocaine dependence
with other forms of substance disorders and psychopathology,
numerous twin studies indicate a high degree of overlap among
genetic factors influencing the liability to a variety of substance use
disorders11,12. Genomic studies have also suggested that there are
genetic loci that have substance-specific effects but also that loci exist
that affect risk for the development of dependence on multiple sub-
stances (see4 for review). Loci that have been largely implicated to
specifically influence a single substance use disorder include those
that exert metabolic influence on the substance of abuse. For
instance, SNPs in cytochrome P450 2A6 (CYP2A6), the gene encod-
ing the major nicotine-metabolizing enzyme, affect cigarette con-
sumption13,14 and a SNP in the Alcohol Dehydrogenase 1B
(ADH1B) gene affects levels of alcohol consumption15 and risk for
alcohol dependence4 via regulation of conversion of alcohol to
acetaldehyde.
On the other hand, there are numerous examples of receptor
encoding loci whose effects extend across multiple substance
dependence phenotypes. One such example is the SNP rs16969968
(D398N) in the cholinergic nicotinic receptor subunit a5 (CHRNA5)
that both increases nicotine dependence risk and decreases cocaine
dependence risk5,16. The minor allele of this SNP is the most signifi-
cant and widely replicated variant associated with cigarette con-
sumption and is also associated with protection against cocaine
dependence5,14,17. The protective effect of rs16969968 with CD has
been replicated in both European and African-Americans16. The
same study also found that another SNP in CHRNA5 (rs684513) is
associated with risk for cocaine dependence in African-Americans
(OR 5 1.43, P 5 0.0004).
In addition, a cluster of nicotinic receptors on chromosome 8
including CHRNB3-A6 was also previously shown to reduce risk
for nicotine-related phenotypes in several GWAS of nicotine
dependence and cigarettes smoked per day13,14,18–23. An overlapping
set of SNPs in the CHRNB3-CHRNA6 region were also reported by
Hartz et al. (2011) to be associated with risk of bipolar disorder24.
Despite the positive correlation between nicotine dependence and
bipolar disorder the associations are in opposite directions, i.e. SNPs
in this locus are associated with reduced risk for nicotine dependence
but increased risk for bipolar disorder. This suggests that the SNPs
affect bipolar disorder independently of their role in nicotine
dependence. The role of these specific SNPs in the etiology of CD
remains unexplored but several rare variants in CHRNB3 have been
associated with increased risk for both cocaine and alcohol depend-
ence25. Together, these results suggest that nicotinic receptors are
good candidate genes for susceptibility to nicotine and cocaine
dependence vulnerability and that investigation of the role of com-
mon and low frequency variants within the CHRNB3-A6 locus in
cocaine dependence is warranted.
In this study, we describe a novel association between DSM-5
cocaine use disorder and genotyped SNPs (,24 kb) upstream of
the CHRNB3 transcription start site. We show that these SNPs
remain significant after adjusting for genotype at the SNP previously
reported to be associated with nicotine dependence in GWAS, sug-
gesting that the cocaine association is not simply due to the nicotine
association.
Results
The 47 SNPs within the CHRNB3-A6 region constitute 22 LD bins
using an r2 cutoff$ 0.8, requiring a p-value of 0.002 after Bonferroni
correction. Eleven SNPs, representing four LD bins met this cutoff
and are associated with DSM-5 cocaine use disorder (Table 1).
Overall, a total of thirty-one SNPs were nominally significant (2.34
3 1024 , p , 4.66 3 1022) in this single SNP analysis. Consistent
with previous results in an overlapping dataset, we saw a protective
effect of rs16969968 in CHRNA5 on risk for DSM-5 cocaine use
disorder [5]. Inclusion of rs16969968 as a covariate had no effect
on the association of the top SNP within CHRNB3-A6, rs9298626
with DSM-5 cocaine use disorder.
Conditional analyses. To determine whether there was evidence for
multiple independently associated variants at this locus contributing
to risk for DSM-5 cocaine use disorder, the most significant SNP in
the region (rs9298626) was added to the model as a covariate.
Conditioning on rs9298626 eliminated the association with SNPs
in LD bins 1 and 2, but the association remained for SNPs in bins
4 and 5. After including rs9298626 as a covariate, the top SNP
associated with this phenotype was rs892413 (p 5 3.57 3 1024,
OR 5 1.58, CI 5 1.23–2.04). The p-value for bin 4 tagged here
by rs11986892 is 0.001, OR 5 1.51, CI 5 1.17–1.94. Similarly the
p-value for bin 5 tagged by rs10107450 is 0.003, OR 5 1.45, CI 5
1.14–1.85. This means that after conditioning on rs9298626,
rs892413 and rs11986892 still pass the multiple test correction
threshold of 0.002, whereas rs10107450 does not, although it does
come close.
Examination of LD shows that the r2 between rs9298626 and
rs892413 is low, suggesting that these SNPs represent independent
association signals (r2 5 0.01; D9 5 0.85). Because the minor
allele frequency for rs9298626 is low, the r2 will never be high but
the D9 indicates that the minor allele of this SNP is usually but not
always on the background of one allele of rs892413. Neither of these
SNPs is in significant LDwith the previously identified genome-wide
significant signal (rs1451240) associated with cigarette consumption
and nicotine dependence14,23 in this region (r2 5 0.14 between
rs9298626 and rs1451240, r2 5 0.35 between rs892413 and
rs1451240; Figure 1), although rs9298626 is in high LD (r2 5 0.94)
with rs4952, another SNP previously reported to be associated with
nicotine dependence18. We find that rs9298626, rs892413 and
rs1451240 correspond to different LD bins using r2 5 0.8 as the
threshold for defining the bins (Table 1). This is consistent with
recent results from our group showing, in an overlapping dataset,
that the genome-wide significant signal in this region, tagged by
rs1451240, is solely associated with nicotine dependence. Taken
together, this suggests that these three SNPs represent different asso-
ciation signals in this region.
Minor allele frequency examination. To determine whether there is
a significant effect of lifetime cocaine exposure on these associations,
we compared the frequency of the minor allele of rs9298626 with
DSM-5 cocaine use disorder, exposed non-dependent individuals
and non-exposed individuals. Control individuals used in our
initial analyses included both those who were exposed to cocaine
but were unaffected (N 5 393 with 0–1 DSM-5 criteria), as well as
those who were never exposed (N 5 1077). The minor allele
frequency of rs9298626 was 9.9% among those with DSM-5
cocaine use disorder and 5.3% among subjects who have been
exposed to cocaine but did not progress to cocaine use disorder.
Non-exposed controls have an intermediate minor allele frequency
of 7.7%, suggesting that both those with DSM-5 cocaine use disorder
and those who were cocaine-exposed non-dependent controls show
allele frequency differences from unselected controls (Table 2),
although the difference in frequency of rs9298626 between
exposed but unaffected controls and unexposed controls was not
significant. When control subjects were restricted to those who
had been exposed to cocaine but were unaffected (n 5 899 vs.
1976), the association between rs9298626 and DSM-5 cocaine use
disorder was reduced but the odds ratio was unchanged (p5 3.123
1023, OR5 2.68, CI5 1.40–5.16), supporting the role of this SNP, or
another SNP in LD with rs9298626, in risk for DSM-5 cocaine use
disorder, even after accounting for cocaine exposure. While the
exposed and unaffected individuals have higher rates of nicotine
and alcohol dependence we conclude that this is likely because
exposure to cocaine, regardless of dependence, is correlated with
other substance use. We conclude that the minor allele of
www.nature.com/scientificreports
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rs9298626 is correlated with cocaine use disorder, which is
strengthened by the fact that there remains an association even
when not considering unexposed individuals in the analysis.
Stratified analysis. Because SAGE is composed of individuals from
three independent studies, each ascertained for a different substance
dependence, we performed stratified analyses both by study and by
nicotine dependence and alcohol dependence to determine if there
existed a subset of subjects in which the association was most
pronounced. The top SNP associated with DSM-5 cocaine use
disorder (rs9298626) in the whole SAGE dataset was significantly
associated with DSM5 cocaine use disorder in the COGA subset and
showed a trend in the same direction in the FSCD and COGEND
subsets. Furthermore, when individuals from the whole dataset were
stratified by DSM-5 alcohol use disorder, or FTND nicotine
dependence there was evidence of association between rs9298626
and cocaine use disorder in both groups (Table 3). This suggests
that the observed associations are not an artifact of ascertainment.
This analysis suggests that this SNP is associatedwithDSM-5 cocaine
use disorder and that the CHRNB3-A6 locus is robustly associated
with DSM-5 cocaine use disorder, regardless of comorbidity or
ascertainment.
Haplotype analysis. To further examine the relationship between
our top variant identified for DSM-5 cocaine use disorder and the
group of variants known to be associated with smoking tagged by
rs1451240, we performed haplotype-based association testing using
rs9298626 and rs1451240. These two SNPs occur on three
haplotypes that occur with a frequency .1% (Table 4). We chose
rs1451240 because it was found to be genome-wide significant for
nicotine dependence in a previous study using the SAGE GWAS
data23. The most common haplotype, composed of the major
alleles of both SNPs, has a frequency of 78%. The haplotype
associated with the highest risk for DSM-5 cocaine use disorder,
has a frequency of 4% and is composed of the minor alleles at both
rs9298626 and rs1451240 (OR 5 3.19 p 5 1.35 3 1024, 95% CI 5
1.64–4.73). A haplotype composed of the major allele at rs9298626
and the minor allele at rs1451240 has a frequency of 18% but was not
associated with DSM-5 cocaine use disorder (p5 0.14). Because the
frequencies and odds ratio of the haplotype with bothminor alleles is
nearly identical to that of the single SNP analysis for rs9298626 and
the fact that the other haplotype containing the minor allele of
rs1451240 is not associated with DSM-5 cocaine use disorder, we
conclude that the functional allele responsible for this association is
in high LD with the low frequency variant, rs9298626.
Cocaine use disorder and nicotine dependence.To further examine
the relationship between nicotine dependence and DSM-5 cocaine
use disorder associations in this region, we performed additional
conditional analyses. In a linear regression model using age, sex,
study, DSM-5 alcohol symptom count, total FTND score and
rs1451240 genotype as covariates, the association with DSM-5
cocaine use disorder remained significant (Table 5). Lastly, the
DSM-5 cocaine use disorder signal remains significant when
conditioning on the two rare variants (rs35327613 and
rs149775276) recently identified by our group to be associated
Table 1 | Top association results for the linear models run for DSM-5 cocaine use disorder. Bolded SNPs passed multiple test
correction (p . 0.002). Maximum FTND is the score from 0–10, L95 and U95 is the 95% confidence interval, and the frequency is in
the SAGE dataset
European-Americans SAGE DSM-5 Cocaine Use Disorder with covariates age, sex, maximum FTND score, DSM-5 alcohol symptom count, study
SNP LD Bin bp N OR L95 U95 Freq P
rs9298626 1 42,647,165 1970 2.62 1.57 4.37 0.04 2.34E-04
rs7844824 1 42,672,170 1970 2.65 1.58 4.46 0.04 2.43E-04
rs4305884 2 42,637,880 1966 2.13 1.42 3.21 0.06 2.69E-04
rs7824160 1 42,705,413 1969 2.50 1.49 4.19 0.04 4.88E-04
rs11986893 4 42,772,016 1971 1.56 1.22 2.01 0.2 4.92E-04
rs7002907 1 42,702,998 1970 2.49 1.49 4.17 0.04 5.03E-04
rs6997994 1 42,702,328 1971 2.49 1.49 4.18 0.04 5.04E-04
rs7815274 1 42,701,740 1967 2.47 1.47 4.15 0.04 6.41E-04
rs4952 1 42,706,222 1971 2.43 1.44 4.08 0.04 8.12E-04
rs10107450 5 42,749,052 1969 1.50 1.18 1.92 0.22 1.04E-03
rs1868859 2 42,634,958 1971 1.85 1.27 2.69 0.07 1.36E-03
rs892413 3 42,733,535 1971 1.48 1.15 1.89 0.2 2.11E-03
rs4950 6 42,671,790 1957 1.42 1.11 1.83 0.22 5.93E-03
rs13280604 6 42,678,743 1971 1.41 1.10 1.80 0.22 7.49E-03
rs1530848 6 42,672,065 1964 1.40 1.09 1.79 0.22 7.53E-03
rs2196128 3 42,737,443 1971 1.37 1.08 1.74 0.23 8.83E-03
rs6997909 6 42,679,406 1971 1.39 1.08 1.78 0.22 9.67E-03
rs6474414 6 42,679,493 1971 1.39 1.08 1.78 0.22 9.67E-03
rs4736835 6 42,666,190 1971 1.39 1.08 1.78 0.22 1.03E-02
rs9298628 3 42,725,148 1968 1.38 1.08 1.76 0.21 1.04E-02
rs6474415 6 42,682,095 1970 1.38 1.08 1.77 0.22 1.05E-02
rs1451240 6 42,665,868 1970 1.38 1.08 1.77 0.22 1.14E-02
rs7004381 6 42,670,318 1971 1.38 1.07 1.77 0.22 1.24E-02
rs13273442 6 42,663,174 1970 1.38 1.07 1.77 0.22 1.25E-02
rs1955185 6 42,668,804 1971 1.37 1.07 1.76 0.22 1.30E-02
rs6474413 6 42,670,221 1971 1.37 1.07 1.76 0.22 1.31E-02
rs16891620 7 42,744,820 1970 1.42 1.06 1.92 0.13 2.00E-02
rs10958726 6 42,655,066 1971 1.34 1.04 1.73 0.21 2.20E-02
rs6474421 12 42,776,255 1969 1.50 1.05 2.14 0.07 2.62E-02
rs10958725 6 42,643,741 1968 1.31 1.02 1.68 0.22 3.37E-02
rs7012713 13 42,711,460 1970 1.65 1.01 2.70 0.04 4.66E-02
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with DSM-IV alcohol and cocaine dependence symptom count26.
This is not surprising given that these rare missense variants are
present on the haplotypes containing the major allele of rs9298626,
whereas the association reported here is with the minor allele. The
fact that the association with cocaine use disorder remains when
conditioning on the genome-wide significant signal with nicotine
dependence in the region, suggests that the association is indepen-
dent and not acting through nicotine dependence.
Figure 1 | LD plot of the region. Values and gray-scale represent r-squared. Importantly, rs9298626, the top SNP associated with DSM-5 cocaine use
disorder and the shared SNP that becomes significant when putting this SNP into the respective model as a covariate (rs892413) are circled in blue, and
SNPs representing the previously discovered association with nicotine dependence (rs1451240, rs6474413, and rs4952) are circled in red.
Table 2 | Characteristics of the sample broken down by: DSM-5 cocaine use disorder, exposed but unaffected, and non-exposed unaffected
DSM-5 Cocaine Use Disorder EAs Exposed Unaffected EAs Non-exposed Unaffected EAs Total
N 5 506 N 5 393 N 5 1077 N 5 1976
Age (years)
mean age 36 38 39 38
,35 37% 26% 35% 34%
35–39 28% 27% 22% 25%
40–44 23% 35% 25% 26%
$45 12% 12% 18% 13%
Male 62% 50% 34% 44%
Female 38% 50% 66% 56%
Nicotine Dependence
FTND 0,1 10% 47% 68% 49%
FTND 2,3 12% 9% 9% 10%
FTND$ 4 78% 44% 23% 41%
DSM-5 Alcohol Use
Disorder
Case 99% 88% 37% 42%
Control 1% 12% 63% 58%
rs9298626minor allele
carrier
Yes 9.9% 5.3% 7.7% 7.8%
No 90.1% 94.7% 92.3% 92.2%
www.nature.com/scientificreports
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Discussion
Wehave shown, in genotyped data from European-Americans in the
SAGE dataset, that there are at least two statistically independent
signals associated with increased risk for DSM-5 cocaine use disorder
in the region of the CHRNB3-A6 nicotinic receptors on chromosome
8. Several SNPs representing the rs9298626 LD bin surpass the mul-
tiple test correction for the region with DSM-5 cocaine use disorder
(p 5 0.002). rs9298626 is also associated with reduced risk for nic-
otine dependence (OR5 0.47, 95%CI5 0.30–0.76, p5 1.803 1023)
in a univariate genetic analysis. This may be due in part to the fact
that, in European ancestry populations, theminor allele of rs9298626
(MAF 5 0.04) occurs almost exclusively on the background of the
more frequent minor allele (MAF 5 0.22) for rs1451240 previously
reported to be genome-wide significantly associated with nicotine
dependence (Table 3). Conditioning on rs1451240 had no effect on
the association with DSM-5 cocaine use disorder (Table 5). This is
not surprising because rs1451240 is not associated with DSM-5
cocaine use disorder in our data (Table 1).
LD bins tagged by rs9298626 and rs892413 each show association
with DSM-5 cocaine use disorder in joint SNP analysis. Analyses
conditioning on rs9298626 reveal that rs892413 is independently
associated with DSM-5 cocaine use disorder. rs892413 is also assoc-
iatedwithDSM-5 cocaine use disorder independent of the previously
identified genome-wide significant association in the region with
nicotine dependence (represented by rs1451240), providing support
for a direct effect of this SNP on higher DSM-5 cocaine use disorder
risk, as opposed to acting through nicotine dependence risk (Tables 3
and 5).
The LDbin containing rs9298626 also contains rs4952 and rs4953,
two low frequency synonymous variants in CHRNB3 that have prev-
iously been reported to be associated with reduced risk for nicotine
dependence18 and increased risk for bipolar disorder (OR5 1.7, 95%,
CI 5 1.2–2.4, p 5 0.001)24. Interestingly the association of rs4952/
rs4953 with cocaine use disorder is in the same direction as the
association with bipolar disorder (risk) but in the opposite direction
to the association with nicotine dependence (protective) suggesting
that CHRNB3 variants have pleiotropic effects on substance use dis-
orders and other psychiatric diseases. Many epidemiological studies
have reported the common co-occurrence of bipolar disorder and
substance dependence27–29. Studies have also implicated shared genes
with substance dependence and bipolar disorder29,30. It is therefore
possible that the high frequency of bipolar disorder and substance
dependence comorbidity is in part due to common underlying gen-
etic risk factors such as the risk alleles in the CHRNB3-A6 locus
reported here.
Our group has previously reported that rare missense variants in
CHRNB3 increase risk for cocaine dependence26. The results
reported here demonstrate that low frequency and common alleles
within the CHRNB3 locus are also associated with increased risk of
DSM-5 cocaine use disorder. Cocaine dependence has now been
associated with SNPs in two different nicotinic receptor gene clus-
ters, on chromosomes 8 and 15 5,26. It is interesting, however, that the
variant on chromosome 15, within CHRNA5 is associated with
decreased risk for cocaine dependence, while rs9298626 and other
variants in the CHRNB3-A6 region are associated with higher (OR5
2.62) risk for DSM-5 cocaine use disorder.
Furthermore, similar to the observation on chromosome 15, the
chromosome 8 locus is associated with opposing effects on the risk
for cocaine dependence and nicotine dependence. The CHRNB3-A6
locus is associated with decreased risk for nicotine dependence and
increased risk for DSM-5 cocaine use disorder. In contrast, in
CHRNA5, the same variant, D398N (rs16969968), increases risk for
nicotine dependence and decreases risk for cocaine dependence.
Furthermore, our data suggest that different but overlapping SNPs
may explain the cocaine and nicotine dependence associations in
CHRNB3-A6 rather than a single SNP causing opposing effects as
was seen on chromosome 15. These results suggest that CHRNA5
and CHRNB3-A6 demonstrate pleiotropic effects on substance
dependence risk.
Nicotinic acetylcholine receptors (nAChR) are expressed in mul-
tiple types of neurons, and have been shown to modulate reward
response for several substances5. For example, work in animals sug-
gests that activation of a3b4 nAChR can increase cocaine self-
administration31. Because comorbidity between substance depend-
encies is so high, it is plausible that these receptors could play a role in
addiction to multiple substances. Most drugs of abuse act on the
mesolimbic dopamine-containing receptors in the brains of humans
and many other mammals. Among other functions, this system is
known to regulatemotivation32,33 and has similar effects acrossmam-
malian species34. Activation and reinforcement of this system is a
necessary part of drug abuse32. The dopaminergic system is therefore
crucial to addiction, however other neurotransmitters besides dopa-
mine affect the mesolimbic system, especially acetylcholine31. The
biological connection between these two systems could be related
to the reversal of the odds ratio for rs16969968, which is protective
for cocaine dependence but a risk factor for nicotine dependence, as
well as our observation that in the CHRNB3-A6 locus on chro-
mosome 8, there are variants associated with protection against nic-
otine dependence, in addition to variants associated with risk for
DSM-5 cocaine use disorder and bipolar disorder. Since the finding
in CHRNA5 on chromosome 15 is the only association with cocaine
dependence to be successfully replicated, it would be interesting to
examine the CHRNB3-A6 region in other datasets that have assessed
cocaine dependence phenotypes, as well as to analyze datasets of
Table 3 | Results of stratified analyses in these groups for
rs9298626 – controls included here are both those who are
exposed and unaffected, as well as those who are unexposed.
European-American DSM-5 Cocaine Use Disorder
N OR 95% CI
P-Value for
rs9298626
Study
COGEND 1077 1.77 0.67–4.62 0.25
COGA 599 2.62 1.25–5.52 0.01
FSCD 294 6.35 0.67–60.43 0.11
Smoking Status
FTND Cases 814 2.31 1.06–5.02 0.03
FTND Controls 1156 2.59 1.22–5.50 0.01
Alcohol Status
DSM-5 Cases 1522 2.41 1.46–3.98 0.0006
DSM-5 Controls 448 7.05 0.52–94.60 0.14
Table 4 | Haplotypes observed in the SAGE GWAS European-
American sample for DSM-5 cocaine use disorder. The grey box
indicates the major allele for that SNP. P-values are denoting sig-
nificance of that haplotype relative to the reference haplotype.
SNPs are arranged in the order they occur on the chromosome.
Covariates used are age, sex, study, DSM-5 alcohol symptom
count, FTND total
Haplotypes DSM-5 Cocaine Use Disorder
rs9298626 rs1451240 Frequency Odds Ratio P-Value
A A 0.04 3.19 1.353 1024
A G ,0.01 9.89 0.89
C A 0.18 1.23 0.14
C G 0.78 - -
www.nature.com/scientificreports
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other ethnicities. Currently, there is no evidence that either of the
variants reported here are correlated with SNPs that have known
functional consequences. However, rs4952 and rs4953 are both syn-
onymous variants in CHRNB3 and may therefore have some, as yet
unknown effect on transcription or translation of CHRNB3 mRNA.
Overall, our findings underscore the comorbidity among drug
dependencies and corroborate the role of nicotinic receptors in
cocaine-related phenotypes. This study represents one of only a
few to implicate specific variants in cocaine dependence phenotypes
and the first to implicate low frequency variants within theCHRNB3-
A6 locus in risk for DSM-5 cocaine use disorder.
Methods
Samples. Subjects were members of the Study of Addiction: Genetics and
Environment (SAGE) dataset, part of the Gene Environment Association Studies
(GENEVA) program of the National Institutes of Health (NIH)Genes, Environment,
and Health Initiative35. SAGE was designed to study alcohol dependence, and as a
result is composed largely of unrelated alcohol-dependent cases (n5 1048) and non-
alcohol-dependent control subjects (n 5 928). The SAGE dataset was ascertained
from 3 large substance dependence datasets: the Collaborative Genetic Study of
Nicotine Dependence (COGEND), the Collaborative Study on the Genetics of
Alcoholism (COGA) and the Family Study of Cocaine Dependence (FSCD)36. For the
purpose of the current analyses, there were 1976 European-Americans as defined
both by self-report and principal components from the GWAS data, whomet criteria
for cocaine use disorder or unaffected controls.
The DSM-5 was published on May 18, 2013, and supersedes the DSM-IV text
revision (DSM-IV-TR) published in 2000. In theDSM-5, theDSM-IV criteria cocaine
abuse and cocaine dependence have been combined into a single cocaine use disorder.
Cocaine use disorder is now divided into mild (2–3 criteria), moderate (4–5 criteria)
and severe (6 or more criteria). A further difference is that whereas in the DSM-IV,
cocaine abuse diagnostic criteria required only one symptom, in the DSM-5 dia-
gnostic criteria, a diagnosis of mild cocaine use disorder requires at least two criteria
to be met. Lastly, the DSM-IV recurrent legal problems criterion for cocaine abuse
was replaced with the new criterion of craving37.We recoded DSM-IV values in SAGE
to DSM-5 for both cocaine and alcohol use, since alcohol use is used as a covariate in
our analyses.
COGEND sample. COGEND was designed as a community based case–control
study of nicotine dependence. COGEND contains current smokers with nicotine
dependence defined by a Fagerstrom Test for Nicotine Dependence (FTND) score$
4 (maximum score of 10) and non-nicotine dependent subjects who had smoked at
least 100 cigarettes and had a lifetime FTND score of zero or one. All subjects were
ascertained from Detroit and St Louis. Out of the 53,000 subjects who were screened
by telephone, 2,800 were interviewed in person and approximately 2,700 donated
blood samples for genetic studies23. COGEND contributed 76 individuals with
cocaine use disorder (54 nicotine dependent cases based on the FTND, 22 non-
dependent smokers) and 1005 individuals without cocaine use disorder (135 nicotine
dependent cases based on the FTND, 870 non-dependent smokers).
COGA sample.Out of more than 11,000 subjects who participated in COGA, a case-
control series of unrelated individuals was selected for SAGE. COGA recruited
subjects in Hartford, Connecticut; Indianapolis, Indiana; Iowa City, Iowa; New York
City, New York; San Diego, California; St Louis, Missouri; andWashington, DC. For
inclusion in SAGE, cases had to meet life-time criteria for DSM-IV alcohol
dependence, the majority of cases were recruited from alcoholism treatment centers.
Control subjects, were both biologically unrelated to cases, and had consumed alcohol
but never experienced any significant alcohol or drug-related problems, according to
the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA)23. COGA
contributed 212 individuals with DSM-5 cocaine use disorder (all 212 of which also
had DSM-5 alcohol use disorder) and 389 individuals without cocaine use disorder
(271 with DSM-5 alcohol use disorder, 118 alcohol drinkers without DSM-5 alcohol
use disorder).
FSCD sample. Subjects in the FSCD were specifically recruited for cocaine use from
chemical dependency treatment units in the greater St Louis metropolitan area. The
Missouri Family Registry identified community-based control subjects and matched
them by age, race, gender and residential zip code. Controls were biologically
unrelated individuals from the same communities who consumed alcohol, but had no
lifetime history of dependence on any substance23. FSCD contributed 218 individuals
with DSM-5 cocaine use disorder and 76 individuals without DSM-5 cocaine use
disorder (51 non-exposed controls and 25 exposed but without DSM-5 cocaine use
disorder).
Genotyping and Q/C. All DNA samples were genotyped on the Illumina Human
1M-Duo beadchip by the Center for Inherited Disease Research (CIDR) at Johns
Hopkins University. After thorough genotype quality control process, 948,758 of the
1,049,008 genotyped SNPs were available for genetic analysis. Sixty-five of these
genotyped SNPs fell within the region containing the CHRNA6 and CHRNB3 genes
on chromosome 8. Of the 65, only SNPs with a minor allele frequency (MAF) .1%
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and a genotyping call rate.0.98 were considered (47 SNPs). Full details regarding the
quality control procedures are provided in the data cleaning report posted on the
GENEVA website (http://www.genevastudy.org/docs/GENEVA_Alcohol_QC_
report_8Oct2008.pdf) and in related publications35,36.
Phenotype. Cocaine use disorder for all members of the SAGE dataset was measured
using the DSM-5 criteria37. As outlined in the manual, 11 criteria (3 abuse, 7
dependence and craving) were combined and cocaine use disorder was scored as the
endorsement of 2 or more of these 11 criteria (N5 506). Unaffected individuals met
zero or one of the DSM-5 criteria (N 5 1470).
Statistical analyses. All analyses were performed on genotyped data. Association
analyses were conducted in PLINK38 for SNPs in the region on chromosome 8
encompassing the a6 and b3 subunits of nicotinic receptors (42600000 kb to
42800000 kb). Logistic regression with DSM-5 cocaine use disorder as the dependent
variable was performed. Covariates included were age at interview as a continuous
variable, gender, study, maximum lifetime FTND score (0–10, based on the
Fagerstro¨m Test of Nicotine Dependence) to control for smoking status, and DSM-5
alcohol use disorder. Study was coded using two dummy variables (yes/no for two of
the three studies) in order to control for differences in ascertainment. Haploview was
run using the genotypes of the study population to determine the number of
independent linkage disequilibrium (LD) bins in the region using a threshold of
r2 $ 0.8. The Bonferroni correction used in this study is p 5 0.002 (0.05/22), as the
number of LD bins in the region examined is 22. A conditional analysis was
conducted including allele dosage for the top associated SNP as a covariate in the
logistic model.
In a case/control division of subjects based on presence or absence of cocaine use
disorder, logistic regressions were run both using as controls only those who had been
exposed to cocaine but had not become dependent (i.e. have used cocaine at least once
in their lifetime) and all non-cocaine-dependent individuals in the sample, regardless
of exposure status.
To improve our understanding of observed associations, the top SNPs identified in
the whole SAGE dataset were examined using the same models described above in
strata of the data defined by study (COGEND, COGA, FSCD), smoking status (FTND
cases and FTND controls), and alcohol use disorder (DSM-5 cases and DSM-5
controls). A two-SNP haplotype analysis was run in R using the top SNP and the SNP
tagging the bin previously found to be genome-wide significant with nicotine
dependence (rs1451240)23. This model included the covariates age, sex, study, DSM-5
alcohol symptom count, FTND total (in the cocaine haplotypes) and DSM-5 cocaine
use disorder (in the FTND haplotypes), and examined the association with each
haplotype with the phenotype compared to homozygotes for the reference allele at
both SNPs. Finally, we used conditional analyses to examine the extent of inde-
pendence between these cocaine-associated SNPs and the previous association in the
region with nicotine dependence tagged by rs1451240.
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